These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 17916465)
1. Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Finke LH; Wentworth K; Blumenstein B; Rudolph NS; Levitsky H; Hoos A Vaccine; 2007 Sep; 25 Suppl 2():B97-B109. PubMed ID: 17916465 [TBL] [Abstract][Full Text] [Related]
6. The first dendritic cell-based therapeutic cancer vaccine is approved by the FDA. Hovden AO; Appel S Scand J Immunol; 2010 Dec; 72(6):554. PubMed ID: 21044130 [No Abstract] [Full Text] [Related]
7. Vaccine therapy in patients with renal cell carcinoma. Van Poppel H; Joniau S; Van Gool SW Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522 [TBL] [Abstract][Full Text] [Related]
8. Whole-cell vaccines: A failure or a success waiting to happen? Copier J; Dalgleish A Curr Opin Mol Ther; 2010 Feb; 12(1):14-20. PubMed ID: 20140812 [TBL] [Abstract][Full Text] [Related]
9. Technical challenges facing therapeutic cancer vaccines. Ward S; Copier J; Dalgleish A Curr Opin Drug Discov Devel; 2008 Mar; 11(2):168-77. PubMed ID: 18283604 [TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines. Part 2. Hallin PA; Adams VR J Am Pharm Assoc (Wash); 1997; NS37(6):706-9. PubMed ID: 9425801 [TBL] [Abstract][Full Text] [Related]
11. Challenges for cancer vaccine development. Tabi Z; Man S Adv Drug Deliv Rev; 2006 Oct; 58(8):902-15. PubMed ID: 16979786 [TBL] [Abstract][Full Text] [Related]
12. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457 [TBL] [Abstract][Full Text] [Related]
13. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. El-Maraghi RH; Eisenhauer EA J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606 [TBL] [Abstract][Full Text] [Related]
14. Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Brockstedt DG; Dubensky TW Expert Rev Vaccines; 2008 Sep; 7(7):1069-84. PubMed ID: 18767955 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccines in melanoma: from promise to proof? Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431 [TBL] [Abstract][Full Text] [Related]
16. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Berinstein NL Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743 [TBL] [Abstract][Full Text] [Related]
17. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052 [TBL] [Abstract][Full Text] [Related]
19. Vaccines: an innovative approach to treating cancer. Pazdur MP; Jones JL J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219 [TBL] [Abstract][Full Text] [Related]
20. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Fournier P; Schirrmacher V Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]